Arbutus Biopharma

ABUSPhase 2

Arbutus Biopharma is a virology-focused biotech leveraging a combination drug development strategy to pursue a functional cure for chronic hepatitis B. Its innovative pipeline, anchored by the RNAi therapeutic imdusiran, employs a 'Suppress, Reduce, Boost' methodology to attack the virus through complementary mechanisms of action. The company is led by an experienced team with a strong track record in drug development, biotech creation, and strategic finance, positioning it to advance its clinical-stage assets toward the market.

Market Cap

$815.5M

Focus

BiologicsRNA & Gene Therapy

AI Company Overview

Technology Platform

A combination therapy platform for viral diseases, specifically employing a 'Suppress, Reduce, Boost' multi-mechanism approach to achieve a functional cure for Hepatitis B.

Pipeline Snapshot

12 drugs in pipeline

Drug	Indication	Stage
AB-729 + Peg-IFNα-2a	Chronic Hepatitis b	Phase 2
Imdusiran (AB-729)	Chronic Hepatitis B	Phase 2
VBR + AB-729 + SOC NrtI	Chronic Hepatitis B	Phase 2
Imdusiran + Durvalumab	Hepatitis B, Chronic	Phase 2
ARB-001467	Hepatitis B, Chronic	Phase 2

Funding History

Total raised: $90M

PIPE$40MRA Capital ManagementJan 15, 2018

PIPE$50MRA Capital ManagementMar 15, 2016

IPOUndisclosedUndisclosedJun 15, 2007

Opportunities

The primary opportunity is capturing a multi-billion dollar market by developing the first finite-duration, functional cure for chronic Hepatitis B, a disease affecting hundreds of millions globally.

Success with its combination regimen could also validate its platform for application against other persistent viral infections.

Risk Factors

Key risks include clinical trial failure of lead assets, intense competition potentially reaching the market first, dependence on raising capital as a pre-revenue company, and the inherent complexity and regulatory challenges of developing combination therapies.

Competitive Landscape

Arbutus competes in a crowded HBV curative landscape against large pharma (Gilead, J&J, GSK) and other biotechs. Its differentiation is its focused, internally-developed combination strategy targeting the virus through three complementary mechanisms (Suppress, Reduce, Boost), guided by deep virology expertise.

Publications

Patents

Pipeline